In:
Diagnostic and Therapeutic Endoscopy, Hindawi Limited, Vol. 7, No. 1 ( 2000-01-01), p. 21-27
Abstract:
Background Since long-term administrations of anti-hyperlipidemic
agents result in reduction in % stenosis or increase in minimum lumen diameter (MLD) of stenotic coronary
segments, it is generally believed that anti-hyperlipidemic agents stabilize vulnerable coronary plaques. However, recent pathologic
and angioscopic studies revealed that vulnerability of coronary plaques is not related to severity of stenosis and the rims rather
than top of the plaques disrupt, and therefore, angiography is not adequate for evaluation of vulnerability. Angioscopy enables macroscopic pathological evaluation of the coronary plaques.
Therefore, we carried out a prospective angioscopic open trial for evaluation of the stabilizing effects of bezafibrate on coronary plaques. Methods From April, 1997 to December, 1998, 24 patients underwent
coronary angioscopy of the plaques in the non-targeted vessels during coronary interventions and 6 months later. The patients
were divided into control (10 patients, 14 plaques) and bezafibrat (14 patients, 21 plaques) groups. Oral
administration of bezafibrate (Bezatol SR, 400mg/day) was started immediately after the interventions and was continued for
6 months. The vulnerability score was determined based on angioscopic characteristics of plaques and it was compared before
and 6 months later. Results Six months later, vulnerability score was reduced
(from 1.6 to 0.8;p 〈 0.05) in bezafibrate group and
unchanged (from 1.4 to 1.3; NS) in control group. In bezafibrate group, the changes in vulnerability score was not
correlated with those in % stenosis or MLD. Conclusion The results indicate that bezafibrate can stabilize coronary plaques.
Type of Medium:
Online Resource
ISSN:
1070-3608
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2000
detail.hit.zdb_id:
2397561-1
